Home / Health / Aspirin Linked to 70% Lower Dementia Risk
Aspirin Linked to 70% Lower Dementia Risk
1 Oct
Summary
- Aspirin may lower dementia risk by 70% in specific genetic groups.
- Study analyzed over 13,500 participants from the ASPREE Trial.
- Aspirin use increased serious bleeding risk by 4.4% in the study.
New research indicates that low-dose aspirin may be associated with a substantial 70% reduction in dementia risk for older adults carrying specific genetic markers influencing platelet count. This discovery stems from an analysis of genetic data from the ASPREE Trial, involving over 13,500 participants.
The study identified that individuals with the highest genetic predisposition for platelet counts, who also took aspirin, experienced a significantly lower incidence of dementia compared to those on a placebo. This suggests a potential for personalized approaches to dementia prevention.
Lead researcher Dr. Peter Fransquet noted that aspirin's preventative effect was not evident in the overall trial population, highlighting the importance of genetic makeup in identifying subgroups who might benefit.
Conversely, the research also revealed a concerning side effect: aspirin use was linked to a higher risk of major bleeding. Aspirin users reported a 4.4% incidence of serious bleeding, compared to 2.1% in the placebo group.
Further independent confirmation and a deeper understanding of the biological links between aspirin, platelet function, and dementia are crucial next steps. Experts caution that these findings, while promising, do not warrant a change in current aspirin recommendations and underscore the need for doctor consultation due to increased bleeding risks.
Researchers hypothesize that aspirin's effect on platelet activation may influence inflammatory processes or vascular factors in the brain related to dementia. If validated, the widespread availability and low cost of aspirin could make personalized dementia prevention a tangible reality.
Physician scientist Dr. Thomas Holland remarked that the findings are promising, reinforcing the idea that dementia prevention is unlikely to be a one-size-fits-all strategy. He stressed that these results do not encourage starting aspirin without medical advice, emphasizing the medication's potential harms.
